Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 6/20 | 0.64 |
| ▸ | CDK1 | P06493 | 6/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.64 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.64 |
| ▸ | RET | P07949 | 5/20 | 0.64 |
| ▸ | FLT3 | P36888 | 3/20 | 0.63 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.63 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.63 |
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | BCR | P11274 | 1/20 | 0.58 |
| ▸ | PRKCA | P17252 | 1/20 | 0.58 |
| ▸ | PRKACA | P17612 | 1/20 | 0.58 |
| ▸ | PRKACG | P22612 | 1/20 | 0.58 |
| ▸ | PRKACB | P22694 | 1/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.58 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31588329 | 0.86 | CCNB2 (0.76) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL144954 | 0.86 | CCNB2 (0.76) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL6254567 | 0.85 | MAP3K14 (0.59) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL4509559 | 0.85 | FLT3 (0.71) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL4518219 | 0.83 | RET (0.79) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL4510383 | 0.82 | FLT3 (0.64) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL4517500 | 0.81 | FLT3 (0.60) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL7467183 | 0.81 | FLT3 (0.60) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL20691186 | 0.81 | EIF2AK2 (0.67) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL12723154 | 0.80 | CDK1 (0.71) | CCNB2CDK1CCNB1CCNB3RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171630-A1 | both receptor-type and non-receptor type tyrosine kinases; to treat angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, | KIM YUNTAE (US) | 2004-09-02 | — | — | US | claimed |
| WO-2002102783-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-12-27 | — | — | WO | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| US-20040171630-A1 | both receptor-type and non-receptor type tyrosine kinases; to treat angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, | KIM YUNTAE (US) | 2004-09-02 | — | — | US | disclosed |
| WO-2002102783-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | CCNB2 2634/4885CDK1 2901/4885CCNB1 3324/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | CCNB2 2634/4885CDK1 2901/4885CCNB1 3324/4885 |
| US-20040171630-A1 | both receptor-type and non-receptor type tyrosine kinases; to treat angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, | KDR, FLT4, FLT1 | CCNB2 1187/4885CDK1 202/4885CCNB1 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.